Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory or Relapsed Classical Hodgkin Lymphoma”

76 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 76 results

Testing effectiveness (Phase 2)Study completedNCT00540007
What this trial is testing

Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma

Who this might be right for
Hodgkin Disease
Washington University School of Medicine 80
Large-scale testing (Phase 3)UnknownNCT04342936
What this trial is testing

Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma

Who this might be right for
Classical Hodgkin Lymphoma
Jiangsu HengRui Medicine Co., Ltd. 56
Not applicableStudy completedNCT06295211
What this trial is testing

Brentuximab Vedotin Combined With Bendamustine Supercharge, a Low-toxicity and Efficient Salvage Regimen for Primary Refractory or First-relapsed Classic Hodgkin Lymphoma: Long-term Results of a Retrospective Monocenter Study.

Who this might be right for
Hodgkin Lymphoma
Federico II University 32
Early research (Phase 1)Looking for participantsNCT05362773
What this trial is testing

MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

Who this might be right for
Leukemia, Acute MyeloidMyelodysplastic SyndromesClassical Hodgkin Lymphoma+5 more
MacroGenics 130
Testing effectiveness (Phase 2)Looking for participantsNCT03681561
What this trial is testing

Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma

Who this might be right for
Hodgkin Lymphoma
Veronika Bachanova 54
Testing effectiveness (Phase 2)Looking for participantsNCT05896046
What this trial is testing

SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma

Who this might be right for
Relapsed or Refractory Hodgkin Lymphoma
Chinese PLA General Hospital 100
Not applicableUnknownNCT04237233
What this trial is testing

Intense Monitoring Study on Tyvyt

Who this might be right for
Relapsed or Refractory Classical Hodgkin's Lymphoma
Innovent Biologics (Suzhou) Co. Ltd. 300
Testing effectiveness (Phase 2)Looking for participantsNCT05039073
What this trial is testing

Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors

Who this might be right for
Recurrent Classic Hodgkin LymphomaRefractory Classic Hodgkin Lymphoma
Emory University 46
Testing effectiveness (Phase 2)UnknownNCT03652441
What this trial is testing

Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma

Who this might be right for
Classical Hodgkin Lymphoma
University of Cologne 21
Testing effectiveness (Phase 2)WithdrawnNCT00298467
What this trial is testing

MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma

Who this might be right for
Lymphoma, Large-Cell
Bristol-Myers Squibb 45
Early research (Phase 1)Active Not RecruitingNCT03150329
What this trial is testing

Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.

Who this might be right for
Grade 3b Follicular LymphomaRecurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic HLRecurrent Classic Hodgkin Lymphoma+13 more
City of Hope Medical Center 52
Testing effectiveness (Phase 2)Active Not RecruitingNCT04938232
What this trial is testing

Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL

Who this might be right for
Hodgkin LymphomaRelapsed Hodgkin's Disease, AdultRefractory Hodgkin Lymphoma
Dana-Farber Cancer Institute 13
Testing effectiveness (Phase 2)UnknownNCT05137886
What this trial is testing

PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma

Who this might be right for
Hodgkin Lymphoma, AdultRelapseRefractory Hodgkin Lymphoma
Institute of Hematology & Blood Diseases Hospital, China 47
Early research (Phase 1)WithdrawnNCT04952584
What this trial is testing

Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Relapsed or Refractory CD30-Positive Lymphomas

Who this might be right for
Extranodal Natural Killer/T-Cell Lymphoma, Nasal TypeClassical Hodgkin Lymphoma
Baylor College of Medicine
Testing effectiveness (Phase 2)Study completedNCT04091490
What this trial is testing

Combination of Nivolumab and DHAP in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (Nivo-DHAP)

Who this might be right for
Hodgkin Lymphoma
State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia 40
Testing effectiveness (Phase 2)Study completedNCT03505996
What this trial is testing

CS1001 in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma

Who this might be right for
Hodgkin Lymphoma
CStone Pharmaceuticals 82
Testing effectiveness (Phase 2)Looking for participantsNCT05243693
What this trial is testing

Brentuximab Vedotin Plus DHAP in Relapsed or Refractory Hodgkin's Lymphoma

Who this might be right for
Relapsed/Refractory Classical Hodgkin Lymphoma
National Cancer Center, Korea 30
Testing effectiveness (Phase 2)UnknownNCT05757466
What this trial is testing

Prolgolimab Monotherapy or in Combination With Bendamustine for r/r Classical Hodgkin Lymphoma

Who this might be right for
Hodgkin Lymphoma
St. Petersburg State Pavlov Medical University 30
Large-scale testing (Phase 3)Ended earlyNCT02951156
What this trial is testing

Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

Who this might be right for
Diffuse Large B-Cell Lymphoma
Pfizer 29
Testing effectiveness (Phase 2)Looking for participantsNCT02332668
What this trial is testing

Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

Who this might be right for
MelanomaLymphomaSolid Tumor+2 more
Merck Sharp & Dohme LLC 370
Load More Results